Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway.
- Author:
Zhong-cheng LIU
1
;
Hai-lang SHI
;
Yan-fen ZHANG
;
Li-jun ZHAO
Author Information
1. Key Laboratory for Drug Quality Control and Analysis of Hebei Province, Baoding 071002, China. liuzc@hbu.edu.cn
- Publication Type:Journal Article
- MeSH:
Aminophenols;
pharmacology;
therapeutic use;
Animals;
Anti-Allergic Agents;
pharmacology;
therapeutic use;
Antibodies, Anti-Idiotypic;
pharmacology;
therapeutic use;
Antibodies, Monoclonal, Humanized;
pharmacology;
therapeutic use;
Humans;
Hypersensitivity;
drug therapy;
immunology;
Immunoglobulin E;
metabolism;
Intracellular Signaling Peptides and Proteins;
antagonists & inhibitors;
Molecular Targeted Therapy;
Omalizumab;
Protein-Tyrosine Kinases;
antagonists & inhibitors;
Pyrimidines;
pharmacology;
therapeutic use;
Receptors, IgE;
metabolism;
Signal Transduction;
Syk Kinase
- From:
Acta Pharmaceutica Sinica
2011;46(10):1161-1166
- CountryChina
- Language:Chinese
-
Abstract:
Allergic diseases have become global social health problems. The binding of IgE with its high affinity receptor FcepsilonRI plays a key step in I-type allergy. Recently, more and more key molecules on the IgE/FcepsilonRI signaling transduction pathway were to be the drug candidates against allergic diseases, with in-depth study of FcepsilonRI signal pathway gradually. The main drugs include molecule antibodies, peptides, vaccines, fusion proteins, small molecules, and other drugs related to IgE/FcepsilonRI. The recent progress in the study of mechanisms of representative drugs targeting on IgE/FcepsilonRI signaling pathway was reviewed in this article.
